A VACCINE that targets the malaria parasite at a vulnerable point in its development could form part of a strategy to eradicate the disease.
Unlike other vaccines in the pipeline, which are designed to protect individuals who have been bitten, this one aims to sabotage the life cycle of the malaria parasite, Plasmodium, by stopping it from passing back from humans to mosquitoes.
While preventing this transmission wouldn’t help an infected individual directly, it would benefit the population as a whole, says the study’s lead author of Johns Hopkins Malaria Research Institute in Baltimore, Maryland. “If you…
